• TRM (USD/COP)COP 3,461.92 +1.37% +COP 46.82Colombia's official exchange rate (Financial Superintendence), valid Nov 21 to Nov 23
  • EuroCOP 3,804.64 +1.37% +COP 51.45Reference: TRM crossed with the European Central Bank rate of Nov 20; not the market quote
  • Mexican pesoCOP 181.56 +1.37% +COP 2.45Reference: TRM crossed with the European Central Bank rate of Nov 20; not the market quote
← Back to the community
General

Why are FTC serial-acquisition lawsuits and state mini-HSR laws breaking the private equity healthcare roll-up model?

Federal antitrust lawsuits targeting serial acquisitions alongside state mini-HSR pre-closing review laws are dismantling the private equity healthcare and veterinary roll-up model by blocking buyout sponsors from stealthily consolidating local medical clinics below federal Hart-Scott-Rodino reporting thresholds to extract regional monopoly pricing.

For over a decade, the classic private equity buy-and-build arbitrage relied on acquiring a platform practice in anesthesiology, dermatology, dental care, or veterinary medicine and executing dozens of bolt-on acquisitions valued under the $119.5 million HSR filing threshold. Once a sponsor captured dominant local market share, it used Management Services Organizations (MSOs) to hike out-of-network billing rates, execute real estate sale-leasebacks, and load the clinical entity with floating-rate debt to fund dividend recapitalizations. However, following the FTC's landmark enforcement actions against U.S. Anesthesia Partners and JAB Consumer Partners' veterinary clinic empire under Section 7 of the Clayton Act, serial roll-ups are now treated as unlawful creeping monopolies.

Even more damaging to buyout Internal Rates of Return (IRRs) is the wave of state-level ”mini-HSR” statutes and Corporate Practice of Medicine (CPOM) crackdowns enacted across California, Oregon, Illinois, New York, and Massachusetts. By empowering state Attorneys General to review, delay, or block sub-threshold healthcare M&A and outlawing MSO control agreements that interfere with clinical staffing, regulators have frozen the traditional multiple-expansion exit pathway. Will this federal and state antitrust offensive protect patients from debt-fueled medical price gouging, or will it starve independent physician and veterinary practices of vital growth capital?

What will be the primary impact of cracking down on PE healthcare roll-ups?

0 votes

Comments

Be respectful. Comments reported by several people are hidden until a moderator reviews them.

You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.